Association between baseline cognition and clinical response in first-episode schizophrenia.
4 affiliations
- 1Department of Psychiatry, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing Brain Hospital, Nanjing, Jiangsu, 210029, PR China.
- 2Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental DisordersThe Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
- 3Department of Psychiatry, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing Brain Hospital, Nanjing, Jiangsu, 210029, PR China. [email protected].
- 4Department of Psychiatry, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing Brain Hospital, Nanjing, Jiangsu, 210029, PR China. [email protected].
Abstract
Background
This study aimed to investigate the association between baseline cognitive performance and the clinical response to antipsychotics in first-episode schizophrenia (FES) patients.Methods
This study examined 769 patients from a multi-center research cohort. Neurocognition was measured using the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia at baseline. Clinical response was defined as ≥ 50% reduction in PANSS total score from baseline to week 8. Pearson correlation analysis was performed for preliminary exploratory assessment. Multivariable logistic regression models (response: yes/no) were fitted with each cognitive domain as dependent variable, adjusted confounding factors. To test effect modification, we added interaction terms: (i) cognition × antipsychotic type and (ii) cognition × baseline illness severity. For domains with significant interactions (P < 0.05), stratified analyses were performed within each drug group and severity stratum.Results
Logistic regression analysis demonstrated that all baseline neurocognitive domains were significantly associated with clinical response (All P < 0.05). Significant interactions between neurocognitive performance and antipsychotics were observed across all domains except Working Memory and Reasoning/problem solving. Similarly, significant interactions between neurocognition and baseline illness severity were found for all domains except Visual and Verbal learning. Further stratified analyses revealed that baseline cognitive performance was associated to clinical response to amisulpride and risperidone. Additionally, significant associations between neurocognition and clinical response were consistently observed in patients with moderate-to-severe illness severity across all domains, with the exception of Visual and Verbal Learning.Conclusions
The association between baseline cognitive performance and treatment response is contingent on medication regimen and baseline illness severity.Trial registration
The study was registered on ClinicalTrials.gov (NCT03451734) with a registration date of January 23, 2018.
Related
- Association of Baseline and Serial High-Sensitivity Cardiac Troponin T with In-Hospital Mortality Across Clinical Presentation, LVEF and Diabetes Status in Decompensated Heart Failure
- Mediating effect of inflammation on the association between glucocorticoid response-related polymorphism and metabolic syndrome in patients with schizophrenia: Evidence from the FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) cohort
- Association of Self-Reported Clinical Behavior With Guideline Adherence in Schizophrenia and Major Depressive Disorder After Guideline Education.
- Association of baseline non-severe anemia with clinical outcomes following the first recorded diagnosis of systemic sclerosis: A matched cohort study.
- B-cell landscape remodelling following dual BAFF/APRIL inhibition with telitacicept in lupus nephritis: extrafollicular axis clearance and its association with clinical response.
BibTeX
@article{zhu2026association,
title = {{Association between baseline cognition and clinical response in first-episode schizophrenia.}},
author = {Yuanyuan Zhu and Ye Yang and Renrong Wu and Dong Cao and Fuli Jiang},
journal = {BMC psychiatry},
year = {2026},
month = aug,
doi = {10.1186/s12888-026-08481-4},
url = {https://europepmc.org/article/MED/42972312},
note = {CC BY},
}
RIS
TY - JOUR
TI - Association between baseline cognition and clinical response in first-episode schizophrenia.
AU - Yuanyuan Zhu
AU - Ye Yang
AU - Renrong Wu
AU - Dong Cao
AU - Fuli Jiang
PY - 2026
DA - 2026/08/05
JO - BMC psychiatry
DO - 10.1186/s12888-026-08481-4
UR - https://europepmc.org/article/MED/42972312
AB - Background This study aimed to investigate the association between baseline cognitive performance and the clinical response to antipsychotics in first-episode schizophrenia (FES) patients.Methods This study examined 769 patients from a multi-center research cohort. Neurocognition was measured using the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia at baseline. Clinical response was defined as ≥ 50% reduction in PANSS total score from baseline to week 8. Pearson correlation analysis was performed for preliminary exploratory assessment. Multivariable logistic regression models (response: yes/no) were fitted with each cognitive domain as dependent variable, adjusted confounding factors. To test effect modification, we added interaction terms: (i) cognition × antipsychotic type and (ii) cognition × baseline illness severity. For domains with significant interactions (P < 0.05), stratified analyses were performed within each drug group and severity stratum.Results Logistic regression analysis demonstrated that all baseline neurocognitive domains were significantly associated with clinical response (All P < 0.05). Significant interactions between neurocognitive performance and antipsychotics were observed across all domains except Working Memory and Reasoning/problem solving. Similarly, significant interactions between neurocognition and baseline illness severity were found for all domains except Visual and Verbal learning. Further stratified analyses revealed that baseline cognitive performance was associated to clinical response to amisulpride and risperidone. Additionally, significant associations between neurocognition and clinical response were consistently observed in patients with moderate-to-severe illness severity across all domains, with the exception of Visual and Verbal Learning.Conclusions The association between baseline cognitive performance and treatment response is contingent on medication regimen and baseline illness severity.Trial registration The study was registered on ClinicalTrials.gov (NCT03451734) with a registration date of January 23, 2018.
SN - 1471-244X
ER -